Many fans are curious about Martin Shkreli's financial success in April 2026. In this article, we dive deep into the assets and career highlights.
What is Martin Shkreli's net worth?
In 2006, Shkreli founded his own hedge fund, Elea Capital Management. The following year, Elea was sued in New York State court by Lehman Brothers. According to the lawsuit, Shkreli made the wrong bet, and when the stock he shorted rose in value, he didn't have the funds to repay Lehman Brothers. The bank won a $2.3 million judgment against Shkreli in October 2007. However, the bank went under before it could collect on the judgment.
In March 2018, he was sentenced to seven years in Federal prison. At this point, a judge in his criminal trial ordered him to forfeit $5 million from his ETrade account and $2.36 million worth of other assets, including aPablo Picassopainting and an unreleasedWu-Tang Clanalbum. After legal defense fees, these were reportedly Martin's full remaining assets.
Martin Shkreli is an Albanian American entrepreneur, hedge fund manager, and convicted felon who has a net worth of $0. At his absolute peak, Martin Shkreli had a peak net worth of $70 million. The majority of that net worth, according to Martin's own legal team, came from his stake in the company he launched, Turing Pharmaceuticals.
In 2017, Shkreli was charged, arrested, and eventually convicted in federal court on two counts of securities fraud and one count of conspiracy to commit securities fraud. The charges were actually not related to his actions with Daraprim.
Martin Shkreli was born on March 17, 1983, in Brooklyn, New York. He and his siblings grew up in a working-class family and neighborhood in Brooklyn. Both his parents immigrated to the United States and worked as janitors. Shkreli attended Hunter College High School. He dropped out before his senior year and completed his diploma requirements at the alternative learning high school City-As-School High School. Shkreli was able to land an internship atJim Cramer's(of CNBC's Mad Money) Wall Street hedge fund. He was just 17. Shkreli attended Baruch College and graduated with a bachelor's degree in business administration in 2004.
In January 2022, Martin was banned from working in the pharmaceutical industry for life and ordered to return the $64.6 million in profits he earned from price-gouging Daraprim.
Shkreli's internship was at the hedge fund Cramer, Berkowitz, and Company. While there, he recommended short-selling the stock of a biotech company called Regeneron that was testing a weight-loss drug. Cramer profited when the price of Regeneron dropped as Shkreli predicted. The SEC also took notice and wanted to know how Shkreli could predict that, but could not find any evidence that he had any insider knowledge or had taken part in any wrongdoing. After four years at Cramer Berkowitz as both an intern and an associate, he departed to work as a financial analyst at two large investment banks.
This close call didn't stop Shkreli–far from it. In 2009, he launched MSMB Capital Management. His strategy with MSMB was to short biotech companies and then go into chat rooms devoted to stock trading and talk about the flaws in those biotech companies. Shkreli made another very bad bet. He sold short 32 million shares of a biotech company the day after the company's stock price dropped. Shkreli did this deal through Merrill Lynch. The stock price recovered, and Shkreli could not cover the position; Merrill Lynch lost $7 million on this trade. MSMB Capital was basically wiped out.
Shkreli earned infamy, public scorn, and the nickname "Pharma Bro" in 2015, thanks to his actions while running Turing. That year, the company acquired the rights to an HIV treatment drug called Darapri. Prior to Turing's purchase, Daraprim had been accessible and affordable for decades. The price for a single pill of Daraprim before Turing was $13.50. Soon after acquiring the rights, Turing increased the price per pill to $750.
In summary, the total wealth of Martin Shkreli reflects strategic moves.
Disclaimer: All net worth figures are estimates based on public data.
